Globalisation and blood safety.
Identifieur interne : 001E16 ( Ncbi/Curation ); précédent : 001E15; suivant : 001E17Globalisation and blood safety.
Auteurs : Albert Farrugia [Australie]Source :
- Blood reviews [ 1532-1681 ] ; 2009.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- MESH :
- blood : Infections.
- microbiology : Plasma.
- transmission : Infections.
- Blood Transfusion, Blood-Borne Pathogens, Global Health, Humans, Infection Control, Risk Factors.
Abstract
Globalisation may be viewed as the growing interdependence of countries worldwide through the increasing volume and variety of cross-border transactions in goods and services, and also through the more rapid and widespread diffusion of technology. Globalisation is not just an economic phenomenon, although it is frequently described as such, but includes commerce, disease and travel, and immigration, and as such it affects blood safety and supply in various ways. The relatively short travel times offered by modern aviation can result in the rapid spread of blood-borne pathogens before measures to counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus included an asymptomatic viraemia. This risk can be amplified by ecological factors which effect the spread of these pathogens once they are transferred to a naïve ecosystem, as happened with West Nile Virus (WNV) in North America. The rationalization and contraction of the plasma products industry may be viewed as one aspect of globalisation imposed by the remorseless inevitability of the market; the effect of this development on the safety and supply of products has yet to be seen, but the oversight and assurance of a shrinking number of players will present particular challenges. Similarly, the monopolization of technology, through patent enforcement which puts access beyond the reach of developing countries, can have an effect on blood safety. The challenges presented to blood safety by globalisation are heightening the tensions between the traditional focus on the product safety - zero risk paradigm and the need to view the delivery of safe blood as an integrated process. As an illustration of this tension, donor deferral measures imposed by globalisation-induced risks such as vCJD and WNV have resulted in the loss of the safest and most committed portion of the blood donor population in many Western countries, leading to an increased risk to safety and supply. It is only through an appreciation of the basic needs of transfusion medicine, including the enunciation of appropriate principles to manage, rather than eliminate, risks, that the challenges imposed by globalisation may be overcome.
DOI: 10.1016/j.blre.2008.10.004
PubMed: 19081166
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001994
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001994
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001871
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001E16
Links to Exploration step
pubmed:19081166Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Globalisation and blood safety.</title>
<author><name sortKey="Farrugia, Albert" sort="Farrugia, Albert" uniqKey="Farrugia A" first="Albert" last="Farrugia">Albert Farrugia</name>
<affiliation wicri:level="1"><nlm:affiliation>Blood and Tissues Unit, Australian Therapeutic Goods Administration, ACT, Australia. albertfarrugia@hotmail.com</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Blood and Tissues Unit, Australian Therapeutic Goods Administration, ACT</wicri:regionArea>
<wicri:noRegion>ACT</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19081166</idno>
<idno type="pmid">19081166</idno>
<idno type="doi">10.1016/j.blre.2008.10.004</idno>
<idno type="wicri:Area/PubMed/Corpus">001994</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001994</idno>
<idno type="wicri:Area/PubMed/Curation">001994</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001994</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001871</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001871</idno>
<idno type="wicri:Area/Ncbi/Merge">001E16</idno>
<idno type="wicri:Area/Ncbi/Curation">001E16</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Globalisation and blood safety.</title>
<author><name sortKey="Farrugia, Albert" sort="Farrugia, Albert" uniqKey="Farrugia A" first="Albert" last="Farrugia">Albert Farrugia</name>
<affiliation wicri:level="1"><nlm:affiliation>Blood and Tissues Unit, Australian Therapeutic Goods Administration, ACT, Australia. albertfarrugia@hotmail.com</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Blood and Tissues Unit, Australian Therapeutic Goods Administration, ACT</wicri:regionArea>
<wicri:noRegion>ACT</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Blood reviews</title>
<idno type="eISSN">1532-1681</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Transfusion</term>
<term>Blood-Borne Pathogens</term>
<term>Global Health</term>
<term>Humans</term>
<term>Infection Control</term>
<term>Infections (blood)</term>
<term>Infections (transmission)</term>
<term>Plasma (microbiology)</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Facteurs de risque</term>
<term>Humains</term>
<term>Lutte contre l'infection</term>
<term>Pathogènes transmissibles par le sang</term>
<term>Plasma sanguin (microbiologie)</term>
<term>Santé mondiale</term>
<term>Transfusion sanguine</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Plasma sanguin</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Plasma</term>
</keywords>
<keywords scheme="MESH" qualifier="transmission" xml:lang="en"><term>Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Blood Transfusion</term>
<term>Blood-Borne Pathogens</term>
<term>Global Health</term>
<term>Humans</term>
<term>Infection Control</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term>
<term>Humains</term>
<term>Lutte contre l'infection</term>
<term>Pathogènes transmissibles par le sang</term>
<term>Santé mondiale</term>
<term>Transfusion sanguine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Globalisation may be viewed as the growing interdependence of countries worldwide through the increasing volume and variety of cross-border transactions in goods and services, and also through the more rapid and widespread diffusion of technology. Globalisation is not just an economic phenomenon, although it is frequently described as such, but includes commerce, disease and travel, and immigration, and as such it affects blood safety and supply in various ways. The relatively short travel times offered by modern aviation can result in the rapid spread of blood-borne pathogens before measures to counteract transmission can be put in place; this would have happened with SARS if the basic life cycle of the SARS virus included an asymptomatic viraemia. This risk can be amplified by ecological factors which effect the spread of these pathogens once they are transferred to a naïve ecosystem, as happened with West Nile Virus (WNV) in North America. The rationalization and contraction of the plasma products industry may be viewed as one aspect of globalisation imposed by the remorseless inevitability of the market; the effect of this development on the safety and supply of products has yet to be seen, but the oversight and assurance of a shrinking number of players will present particular challenges. Similarly, the monopolization of technology, through patent enforcement which puts access beyond the reach of developing countries, can have an effect on blood safety. The challenges presented to blood safety by globalisation are heightening the tensions between the traditional focus on the product safety - zero risk paradigm and the need to view the delivery of safe blood as an integrated process. As an illustration of this tension, donor deferral measures imposed by globalisation-induced risks such as vCJD and WNV have resulted in the loss of the safest and most committed portion of the blood donor population in many Western countries, leading to an increased risk to safety and supply. It is only through an appreciation of the basic needs of transfusion medicine, including the enunciation of appropriate principles to manage, rather than eliminate, risks, that the challenges imposed by globalisation may be overcome.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001E16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:19081166 |texte= Globalisation and blood safety. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:19081166" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |